Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat

Toxicology

Volumn 236, Issue 3, 2007, Pages 217-226

  Fillmann, Henrique ^a   Kretzmann, Nelson A ^a   San Miguel, Beatriz ^c   Llesuy, Susana ^b   Marroni, Norma ^a   González Gallego, Javier ^c   Tuñón, María J ^c  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c UNIVERSITY OF LEÓN   (Spain)

Author keywords

Acetic acid; Colitis; Glutamine; Nuclear factor kappaB; Oxidative stress

Indexed keywords

ACETIC ACID; CYCLOOXYGENASE 2; GLUTAMINE; HYDROPEROXIDE; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; SYNAPTOTAGMIN I; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANORECTAL PRESSURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; COLITIS; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ACETIC ACID; ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL RESPONSE MODIFIERS; COLITIS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GLUTAMINE; GLUTATHIONE PEROXIDASE; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 34250902480     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.04.012     Document Type: Article

References (66)

1. Ardite E., Panes J., Miranda M., Salas A., Elizalde J.I., Sans M., Arce Y., Bordas J.M., Fernandez-Checa J.C., and Pique J.M. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br. J. Pharmacol. 124 (1998) 431-433
2. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., and Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95 (2000) 3452-3457
3. Bantel H., Schmitz M.L., Raible A., Gregor M., and Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J. 16 (2002) 1832-1834
4. Brasil L.J., San Miguel B., Gomes do Amaral J.L., Zettler C.G., Marroni N., González-Gallego J., and Tuñón M.J. Halothane induces oxidative stress and NF-κB activation in rat liver: protective effect of propofol. Toxicology 227 (2006) 53-61
5. Curi R., Lagranha C.J., Doi S.Q., Sellitti D.F., Procopio J., Pithon-Curi T.C., Corless M., and Newsholme P. Molecular mechanisms of glutamine action. J. Cell Physiol. 204 (2005) 392-401
6. Deger C., Erbil Y., Giris M., Yanik B.T., Tunca F., Olgac V., Abbasoglu S.D., Oztezcan S., and Toker G. The effect of glutamine on pancreatic damage in TNBS-induced colitis. Dig. Dis. Sci. 51 (2006) 1841-1846
7. Di Paola R., Mazzoni E., Patel N.S., Genovese T., Thiemermann C., De Sarro A., and Cuzzocrea S. Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid. Eur. J. Pharmacol. 507 (2005) 281-289
8. Elias M., and Lunn P. The use of glutamine in the treatment of gastrointestinal disorders in man. Nutrition 13 (1997) 743-747
9. El-Medany A., Mahgoub A., Mustafa A., Arafa M., and Morsi M. The effects of selective cyclooxygenase-2 inhibitors, celcoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur. J. Pharmacol. 507 (2005) 291-295
10. Fillmann H.S., Llesuy S., Marroni C.A., Fillmann S.L., and Marroni N. Diabetes mellitus and anal sphincter pressures: An experimental model in rats. Dis. Colon Rectum 50 (2007) 517-522
11. Flohé L., and Gunzler W.A. Assays of glutathione peroxidase. Meth. Enzimol. 105 (1984) 114-121
12. García-Mediavilla M.V., Crespo I., Collado P.S., Esteller A., Sánchez-Campos S., Tuñón M.J., and González-Gallego J. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur. J. Pharmacol. 557 (2007) 221-229
13. Giris, M., Erbil, Y., Dogru-Abbasoglu, S., Yanik, B. T., Alis, H., Olgac, V., Toker, G. A., 2007. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. Int. J. Colorectal Dis., doi 10.1007/s00384-006-0238-y.
14. Gonzalez-Flecha B., Llesuy S., and Boveris A. Hydroperoxide-initiated chemoluminescence: NA assay for oxidative stress in biopsies of liver, heart, and muscle. Free Rad. Biol. Med. 10 (1991) 41-47
15. Grisham M.B. Oxidants and free radicals in inflammatory bowel disease. Lancet 344 (1994) 859-861
16. Grisham M.B., and Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease. Ann. NY Acad. Sci. 664 (1992) 103-115
17. Gutierrez M.B., Villares C., Tuñón M.J., and González-Gallego J. Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-κB activation or iNOS expression. Toxicology 222 (2006) 125-131
18. Inoue Y.I., Grant J.P., and Snyder P.J. Effect of glutamine-supplemented total parenteral nutrition on recovery of the small intestine after starvation atrophy. J. Parent. Ent. Nutr. 17 (1993) 165-170
19. Ishiguro K., Ando T., Maeda O., Hasegawa M., Kadomatsu K., Ohmiya N., Niwa Y., Xavier R., and Goto H. Paeonol attenuates TNBS-induced colitis by inhibiting NF-κB and STAT-1 transactivation. Toxicol. Appl. Pharmacol. 217 (2006) 35-42
20. Israeli E., Berenshtein E., Wegrower D., Aptekar L., Kohen R., Zajicek G., and Goldin E. Prophylactic administration of topical glutamine enhances the capability of the rat colon to resist inflammatory damage. Dig. Dis. Sci. 49 (2004) 1705-1712
21. Jiang Y.T., Mai G.F., Wang J.D., Zhang Y.L., Luo R.C., and Fang Y.X. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J. Gastroenterol. 28 (2005) 1747-1752
22. Jobin C., and Sartor R.B. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am. J. Physiol. 278 (2000) C451-C462
23. Jurjus A.R., Khoury N.N., and Reimund J.M. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Meth. 20 (2004) 81-92
24. Kaya E., Gür E.S., Özguc H., Bayer A., and Tokyay R. l-glutamine enemas attenuate mucosal injury in experimental colitis. Dis. Colon Rectum 42 (1999) 1209-1215
25. Kankuri E., Vaali K., Korpela R., Paakari I., Vapaatalo H., and Moilanen E. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 25 (2001) 301-310
26. Kruidener L., Kuiper I., Lamers C.B., and Verspaget I. Intestinal oxidative damage in inflammatory bowel disease: semi quantification, localization and association with mucosal antioxidants. J. Pathol. 201 (2003) 28-36
27. Kwon K.H., Murakami A., Tanaka T., and Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem. Pharmacol. 69 (2005) 395-406
28. Li J.H., Yu J.P., Yu H.G., Xu X.M., Yu L.L., Liu J., and Luo H.S. Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Med. Inflamm. 4 (2005) 185-192
29. Lih Brody L., Powel S.R., Collier K.P., Reddy G.M., Cerchia R., and Mullin G.E. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 41 (1996) 2078-2086
30. MacMaster J.F., Dambach D.M., Lee D.B., Berry K.K., Qiu Y., Zusi F.C., and Burke J.R. An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulphate sodium-induced colitis in mice. Inflamm. Res. 51 (2003) 508-511
31. Mahgoub A., El-Medany A., Mustafa A., Arafah M., and Moursi M. Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats. Toxicol. Appl. Pharmacol. 205 (2005) 43-52
32. Martin A.R., Villegas I., Sanchez-Hidalgo M., and de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147 (2006) 873-885
33. Martínez-Flores S., Gutierrez-Fernández B., Sánchez-Campos S., González-Gallego J., and Tuñón M.J. Quercetin prevents nitric oxide production and nuclear factor kappa B activation in interleukin-1β-activated rat hepatocytes. J. Nutr. 135 (2005) 1359-1365
34. Mazzon E., and Cuzzocrea S. Role of iNOS in hepatocyte tigh junction in a mouse model of experimental colitis. Cell Mol. Biol. 49 (2003) 45-57
35. Morris G.P., Beck P.L., and Herridge M.S. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 780-795
36. Necefli A., Tulunoglu B., Giris M., Barbaros U., Olgac V., Guloghi R., and Toker G. The effect of melatonin on TNBS-induced colitis. Dig. Dis. Sci. 51 (2006) 1538-1545
37. Neurath M.F., Fuss I., Schurmann G., Petterson S., Arnold K., Muller-Lobeck H., Strober W., Herfarth C., and Buschenfelde K.H. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann. NY. Acad. Sci. 17 (1998) 149-159
38. Ockenga J., Borchert K., Stuber E., Lochs H., Manns M.P., and Bischoff S.C. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur. J. Clin. Nutr. 59 (2005) 1309-1312
39. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
40. Oz H.S., Chen T.S., McClain C.J., and De Villiers W.J.S. Antioxidants as novel therapy in a murine model of colitis. J. Nutr. Biochem. 16 (2005) 297-304
41. Pastor A., Collado P.S., Almar M., and González-Gallego J. Antioxidant enzyme status in biliary-obstructed rats: effects of N-acetylcysteine. J. Hepatol. 27 (1997) 363-367
42. Pravda J. Radical induction theory of ulcerative colitis. World J. Gastroenterol. 11 (2005) 2371-2384
43. Perez-Navarro R., Ballester I., Zarzuelo A., and Sánchez de Medina F. Disturbances in epithelial ionic secretion in different experimental models of colitis. Life Sci. 76 (2005) 1489-1501
44. Ramachandran A., and Prabhu R. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxigen free radicals. Hepatology 35 (2002) 622-629
45. Roth E., Oehler R., Manhart N., Exner R., Wessner B., Strasser E., and Spittler A. Regulative potential of glutamine: relation to glutation metabolism. Nutrition 18 (2002) 217-221
46. Rugveit J., and Llarsldsen G. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14 + L1 + monocyte-derived cells. Gut 37 (1995) 367-373
47. Sanchez-Hidalgo M., Martin A.R., Villegas I., and Alarcon de la Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 69 (2005) 1733-1744
48. Sandborn W.J., Tremaine W.J., Schroeder K.W., and Steiner B.L. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am. J. Gastroenterol. 88 (1993) 640-645
49. Sartor R.B. Pathogenic and clinical relevance of cytokines in inflammatory bowel disease. Immunol. Res. 10 (1991) 465-471
50. Schottelius A.J., and Baldwin Jr. A.S. A role for transcription factor NF-kappa B in intestinal inflammation. Int. J. Colorectal Dis. 14 (1999) 18-28
51. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42 (1998) 477-484
52. Segui J., Gil F., Gironella M., Alvarez M., Gimeno M., Coronel P., Closa D., Pique J.M., and Panes J. Down-regulation of endothelial adhesion molecules and leukocyte adhesion by treatment with superoxide dismutase is beneficial in chronic immune experimental colitis. Inflamm. Bowel Dis. 11 (2005) 872-882
53. Shinozaki M., Saito H., and Muto T. Excess glutamine exacerbates trinitrobenzenesulfonic acid-induced colitis in rats. Dis. Colon Rectum 40 (1997) S59-S63
54. Siddiqui A., Ancha H., Tedesco D., Lightfoot S., Stewart C.A., and Harty R.F. Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis. Dig. Dis. Sci. 51 (2006) 698-705
55. Sido B., Seel C., Hochlehnert A., Breitkreutz R., and Droge W. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation?. Dig. Dis. Sci. 51 (2006) 172-179
56. Simões A., Porawski M., Alonso M., Collado P.S., Marroni N., and González-Gallego J. Quercetin prevents oxidative stress and NF-kappaB activation in liver of type 1 diabetic rats. J. Nutr. 135 (2005) 299-304
57. Singer I.I., Kawaka D.W., Schloemann S., Tessner T., Riehl T., and Stenson W.F. Cycloxygenase-2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115 (1998) 297-306
58. Talero, E., Sánchez-Fidalgo, S., Calvo, J. R., Motilva, V., 2007. Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regulatory Pept., doi 10.106. regpep. 2006.12.029.
59. Tremel H., Kienle B., Weilemenn L.S., Stehle P., and Fürst P. Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill. Gastroenterology 107 (1994) 1595-1601
60. Tuñón M.J., Sánchez-Campos S., Gutiérrez B., and González-Gallego J. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappaB activation in rat hepatocytes. Biochem. Pharmacol. 66 (2003) 439-445
61. Ukil A., Maity S., and Das P.K. Protection from experimental colitis by theaflavin-3,3′-digallate correlates with inhibition of IKK and NF-kappaB activation. Br. J. Pharmacol. 149 (2006) 121-131
62. Williams J.G., Hughes L.E., and Hallett M.B. Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease. Gut 31 (1990) 187-193
63. Wilmore D.W., and Shaber J.S. Role of glutamine in immunologic response. Nutrition 14 (1998) 618-626
64. Yamada T., Marshall S., Specian R.D., and Grisham M.B. A comparative analysis of two models of colitis in rats. Gastroenterology 102 (1991) 1524-1534
65. Yunus Y., Yuksel M., and Berrak C. The effect of antioxidant therapy on colonic inflammation in the rat. Res. Exp. Med. 199 (1999) 101-110
66. Zingarelli B., Szabo C., and Salzman A.L. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45 (1999) 199-209